Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.

ABSTRACT: The immune checkpoint inhibitor nivolumab inhibits the programmed death 1 receptor and suppresses the immune resistance of cancer cells. This is a long-term follow up of a single-arm, open-label, multicenter, phase II study of nivolumab in untreated Japanese patients with stage III/IV or recurrent melanoma. In addition, a post-hoc subgroup analysis stratified by melanoma types was performed. Nivolumab was administered intravenously at a dose of 3 mg/kg every 2 weeks. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), best overall response, the disease control rate and change in tumor diameter. Safety was assessed by recording treatment-related adverse events (TRAE), including select immune-relat

SUBMITTER: Yamazaki N 

PROVIDER: S-EPMC6549931 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature